The safety of antiretroviral drugs

Expert Opinion on Drug Safety

Volumn 7, Issue 1, 2008, Pages 1-4

  Tymchuk, Christopher N ^a   Currier, Judith S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral; ARV; HIV; Human immunodeficiency virus; Safety; Toxicity

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR ANTAGONIST; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; MARAVIROC; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TIPRANAVIR; VICRIVIROC; ZIDOVUDINE;

ANEMIA; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDITORIAL; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LETHARGY; LIPOATROPHY; LIPOHYPERTROPHY; MALAISE; MUCORMYCOSIS; NAUSEA; NONHODGKIN LYMPHOMA; OSTEOPOROSIS; PANCREATITIS; RASH; SLEEP DISORDER; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; TOXIC HEPATITIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; DRUG HYPERSENSITIVITY; HIV INFECTIONS; HUMANS;

EID: 38949136660     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.1.1     Document Type: Editorial

References (16)

1. Gallant JE, Dejesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efevirenz for HIV. N Engl J Med 2006;354:251-60
2. Eron J, Yeni P, Gathe J, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006;368:476-82
3. Markowitz M, Nguyen B-Y, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. JAIDS 2007;46:125-33
4. Hetherington S, McGuirk S. Powell G, et al. Hypersensitivity reactions during therapy with the nudeoside reverse transcriptase inhibitor abacavir. Clin Ther 2001;23:1603-14
5. *5701, HLADR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-32
6. Phillips EJ. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Clin Infect Dis 2006;43:103-5
7. Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian Human Immunodeficiency Virus Cohort. Clin Infect Dis 2006;43:99-102
8. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35
9. http//www.fda.gov/medwatch/safety/2006/Aptivus-tipranavir_DHCP.pdf Released 2006
10. Gulick RM, Zhaohui S, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1 infected, treatment-experienced patients: AIDS clinical trials group 5211 J Infect Dis 2007;196:304-12
11. Nelson M, Fatkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results [abstract 104aLB]. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retrovirology and Human Health; 2007. p. 102
12. Lalezari J, Goodrich J, Dejesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/ 3 study in the US and Canada [abstract 104bLB]. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retrovirology and Human Health; 2007. p. 103
13. Merchant S, Reichman R, Koval CE. Rhinocerebral zygomycosis in an HIV-infected man during therapy with an investigational CCR5 inhibitor. AIDS 2007;21:1666-9
14. Subbaraman R, Chaguturu SK, Mayer KH, et al. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 2007;45:1093-101
15. Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 2007;45:254-60
16. Geddes R, Knight S, Moose MYS, et al. A high incidence of nucleoside reverse tranacriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J 2006;96:722-4